In the current study, using a HPV peptide therapeutic vaccine employing the combination of adjuvants and intranasal delivery, we could achieve high curative efficacy against established TC-1–Luc vaginal tumors with significant expression of the E6 and E7 oncoproteins in immunocompetent mice with a significant enhancement of functional, HPV-specific anti-tumor CD8 T cell response within the tumors as well as in systemic compartments. This evidence concerns the gene CD8A and vaginal neoplasm.